^
    23h
    Phase I/II Trial of Pembrolizumab and Androgen-receptor Inhibitor With or Without 225Ac-J591 for Progressive Metastatic Castration Resistant Prostate Cancer (clinicaltrials.gov)
    P1/2, N=52, Recruiting, Weill Medical College of Cornell University | Active, not recruiting --> Recruiting | N=37 --> 52
    Enrollment open • Enrollment change
    |
    CELLSEARCH®
    |
    Keytruda (pembrolizumab) • Xtandi (enzalutamide) • Ac-225 rosopatamab tetraxetan (CONV01-α)
    5d
    Study of Radspherin® in Recurrent Ovarian Cancer Subjects With Peritoneal Carcinomatosis (clinicaltrials.gov)
    P1, N=21, Completed, Oncoinvent Solutions AS | Active, not recruiting --> Completed | N=49 --> 21
    Trial completion • Enrollment change • Platinum sensitive • First-in-human
    |
    Radspherin
    9d
    Study of RYZ401 in Subjects With Solid Tumors Expressing SSTRs. (clinicaltrials.gov)
    P1, N=104, Recruiting, RayzeBio, Inc. | Not yet recruiting --> Recruiting | Trial completion date: Oct 2032 --> Apr 2033
    Enrollment open • Trial completion date • First-in-human
    |
    SSTR (Somatostatin Receptor)
    |
    SSTR positive
    9d
    RYZ101-101: Study of RYZ101 in Combination With SoC in Subjects With SSTR+ ES-SCLC (clinicaltrials.gov)
    P1, N=21, Active, not recruiting, RayzeBio, Inc. | N=49 --> 21 | Trial completion date: Mar 2029 --> Jul 2027 | Recruiting --> Active, not recruiting
    Enrollment closed • Enrollment change • Trial completion date
    |
    PD-L1 (Programmed death ligand 1) • SSTR (Somatostatin Receptor)
    |
    Tecentriq (atezolizumab) • carboplatin • etoposide IV • Actinium-225 DOTATATE (RYZ101)
    9d
    Study of the Theranostic Pair RYZ811 (Diagnostic) and RYZ801 (Therapeutic) to Identify and Treat Subjects With GPC3+ (Glypican-3) Unresectable HCC (clinicaltrials.gov)
    P1/2, N=590, Recruiting, RayzeBio, Inc. | Phase classification: P1 --> P1/2 | N=70 --> 590 | Trial completion date: Jan 2031 --> Jun 2031 | Trial primary completion date: Mar 2029 --> Jun 2030
    Phase classification • Enrollment change • Trial completion date • Trial primary completion date
    13d
    SHARP: Radium Ra 223 Dichloride, Hormone Therapy and Stereotactic Body Radiation Therapy in Treating Patients With Metastatic Prostate Cancer (clinicaltrials.gov)
    P2, N=25, Active, not recruiting, City of Hope Medical Center | Trial completion date: Feb 2026 --> Jan 2027
    Trial completion date
    |
    Eligard (leuprolide acetate) • goserelin acetate • Firmagon (degarelix) • Xofigo (radium Ra-223 dichloride) • Viadur (leuprorelin implant)
    14d
    AlphaBreak: FPI-2265 (225Ac-PSMA-I&T) for Patients With PSMA-Positive Metastatic Castration-Resistant Prostate Cancer (mCRPC) (clinicaltrials.gov)
    P2, N=110, Active, not recruiting, Fusion Pharmaceuticals Inc. | Trial primary completion date: Jul 2026 --> Dec 2026 | Recruiting --> Active, not recruiting
    Enrollment closed • Trial primary completion date
    |
    BRCA (Breast cancer early onset)
    |
    BRCA mutation • FOLH1 positive
    |
    FPI-2265
    14d
    Study of [212Pb]Pb-DOTAM-MAM279 ([212Pb]Pb-MP0712) in Patients With Small Cell Lung Cancer and Other DLL3 Expressing Solid Tumors (clinicaltrials.gov)
    P1/2, N=138, Recruiting, Molecular Partners AG | Initiation date: Jan 2026 --> Apr 2026
    Trial initiation date
    |
    DLL3 (Delta Like Canonical Notch Ligand 3)
    |
    DLL3 expression
    15d
    ARTISAN: Study of Alpha Radioligand Therapy AB001 in Patients With Metastatic Castration Resistant Prostate Cancer (mCRPC) (clinicaltrials.gov)
    P1, N=80, Active, not recruiting, ARTBIO Inc. | Recruiting --> Active, not recruiting
    Enrollment closed
    |
    AB001
    15d
    ALPHAMEDIX 02: Targeted Alpha-emitter Therapy of PRRT Naïve and Previous PRRT Neuroendocrine Tumor Patients (clinicaltrials.gov)
    P2, N=69, Active, not recruiting, Orano Med LLC | Trial completion date: Oct 2028 --> Dec 2030 | Trial primary completion date: Oct 2028 --> Apr 2025
    Trial completion date • Trial primary completion date
    |
    SSTR (Somatostatin Receptor)
    |
    AlphaMedix (SAR447873)
    17d
    DUET study: DUET-study: A FEASIBILITY STUDY OF 177LU-PSMA RADIOLIGAND THERAPY ALTERNATED WITH RADIUM-223 IN PATIENTS WITH BONE-METASTATIC, OLIGO-METASTATIC HORMONE-SENSITIVE PROSTATE CANCER AFTER CURATIVE THERAPY. (2024-518985-29-02)
    P1/2, N=6, Completed, Amsterdam UMC Stichting | Active, not recruiting --> Completed
    Trial completion
    |
    FOLH1 expression
    |
    Xofigo (radium Ra-223 dichloride)
    19d
    MTI201-IA: Targeted Alpha Particle Radiotherapy for Metastatic Uveal Melanoma (clinicaltrials.gov)
    P1, N=16, Active, not recruiting, Modulation Therapeutics, Inc. | Recruiting --> Active, not recruiting | Trial primary completion date: Mar 2026 --> Mar 2027
    Enrollment closed • Trial primary completion date • First-in-human